COPENHAGEN (Reuters) - Denmark's Novo Nordisk lifted third-quarter core profit by 40 percent and above expectations on the back of strong sales of diabetes drug Victoza and modern insulins.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
No comments:
Post a Comment